文献速递创伤与烧伤复苏、休克与脓毒症

创伤患者使用复苏性血管内球囊阻断主动脉后腹股沟入路并发症发生率的Meta分析

A meta-analysis of the incidence of complications associated with groin access after the use of resuscitative endovascular balloon occlusion of the aorta in trauma patients.
PubMed 文献 · J Trauma Acute Care Surg · 2018-01-01
一句话结论成人创伤患者REBOA腹股沟入路相关并发症发生率为4%–5%,其中因血管穿刺直接导致的下肢截肢为0.7%。

本系统综述与Meta分析纳入MEDLINE和EMBASE中13项研究、共424例接受REBOA置入的成人创伤患者,评估腹股沟入路相关并发症发生率。REBOA最常由创伤外科医生或急诊科医生置入;经皮穿刺304例(73.4%),外科切开110例(26.5%)。腹股沟入路相关并发症总体发生率为5.6%(24/424),下肢截肢2.1%(9/424),其中3例(0.7%)与REBOA置入的血管穿刺直接相关。采用logit变换的Meta分析显示并发症发生率为5%(95%CI 3%–9%),异质性无统计学意义(LR检验:χ=0.73,P=0.2,Tau平方=0.2);采用Freeman-Tukey双反正弦变换的Meta分析显示并发症发生率为4%(95%CI 2%–7%),异质性低(I=16.3%)。作者认为目前尚无基准或质量指标可供比较,需进一步工作以确定这些基准并改进创伤外科中REBOA的实践。

要点

  • 成人创伤患者REBOA腹股沟入路相关并发症总体发生率为5.6%(24/424),Meta分析合并发生率为4%–5%。
  • 下肢截肢发生率为2.1%(9/424),其中仅3例(0.7%)与REBOA置入的血管穿刺直接相关。
  • 经皮穿刺304例(73.4%),外科切开110例(26.5%);REBOA最常由创伤外科医生或急诊科医生置入。
  • 采用logit变换的Meta分析并发症发生率为5%(95%CI 3%–9%),异质性无统计学意义(LR检验:χ=0.73,P=0.2,Tau平方=0.2)。
  • 采用Freeman-Tukey双反正弦变换的Meta分析并发症发生率为4%(95%CI 2%–7%),异质性低(I=16.3%)。

适用人群与场景

  • 成人创伤患者,接受REBOA置入者。

研究设计与关键结果

  • 系统综述与Meta分析纳入13项研究、共424例成人创伤患者,评估REBOA腹股沟入路相关并发症发生率。
  • REBOA最常由创伤外科医生或急诊科医生置入;穿刺技术信息在12项研究中报告,共414例患者可获取。
  • 经皮穿刺304例(73.4%),外科切开110例(26.5%)。
  • 腹股沟入路相关并发症总体发生率为5.6%(24/424);下肢截肢2.1%(9/424),其中3例(0.7%)与REBOA置入的血管穿刺直接相关。
  • 采用logit变换的Meta分析显示并发症发生率为5%(95%CI 3%–9%),异质性无统计学意义(LR检验:χ=0.73,P=0.2,Tau平方=0.2)。
  • 采用Freeman-Tukey双反正弦变换的Meta分析显示并发症发生率为4%(95%CI 2%–7%),异质性低(I=16.3%)。

证据类型、等级与局限

  • 证据类型:系统综述与Meta分析,证据等级为level III。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为目前尚无基准或质量指标可供比较,需进一步工作以确定这些基准并改进创伤外科中REBOA的实践。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Serious complications related to groin access have been reported with the use of resuscitative endovascular balloon occlusion of the aorta (REBOA). We performed a systematic review and meta-analysis to estimate the incidence of complications related to groin access from the use of REBOA in adult trauma patients.

METHODS: We identified articles in MEDLINE and EMBASE. We reviewed all studies that involved adult trauma patients who underwent the placement of a REBOA and included only those that reported the incidence of complications related to groin access. A meta-analysis of proportions was performed.

RESULTS: We identified 13 studies with a total of 424 patients. REBOA was inserted most commonly by trauma surgeons or emergency room physicians. Information regarding puncture technique was reported in 12 studies and was available for a total of 414 patients. Percutaneous access and surgical cutdown were performed in 304 (73.4%) and 110 (26.5%) patients, respectively. Overall, complications related to groin access occurred in 5.6% of patients (n = 24/424). Lower limb amputation was required in 2.1% of patients (9/424), of which three cases (3/424 [0.7%]) were directly related to the vascular puncture from the REBOA insertion. A meta-analysis that used the logit transformation showed a 5% (95% CI 3%-9%) incidence of complications without significant heterogeneity (LR test: χ = 0.73, p = 0.2, Tau-square = 0.2). In a second meta-analysis, we used the Freeman-Tukey double arcsine transformation and found an incidence of complications of 4% (95% CI 2%-7%) with low heterogeneity (I = 16.3%).

CONCLUSION: We found that the incidence of complications related to groin access was of 4-5% based on a meta-analysis of 13 studies published worldwide. Currently, there are no benchmarks or quality measures as a reference to compare, and thus, further work is required to identify these benchmarks and improve the practice of REBOA in trauma surgery.

LEVEL OF EVIDENCE: Systematic review and meta-analysis, level III.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Manzano-Nunez R, Orlas CP, Herrera-Escobar JP, et al. A meta-analysis of the incidence of complications associated with groin access after the use of resuscitative endovascular balloon occlusion of the aorta in trauma patients. J Trauma Acute Care Surg. 2018. PMID: 29787536. doi:10.1097/TA.0000000000001978

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。